Paris

• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended
  2023-506963-32-00 7 Participants with Phenylketonuria
• A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem … Ended
  2023-507207-66-00 5 Diabetic Macular Edema (DME)
• A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic … Ended
  2023-507344-36-01 4 Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Sq
• Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study Ended
  2023-507452-77-00 3 Recurrent Pericarditis
• ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati … Ended
  2023-509227-41-00 4 Low risk of disease recurrence, defined by the following criteria: - A
• Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy Ended
  2023-509615-92-00 4 Ischemic stroke with Large Core
• A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease Ended
  2023-510289-28-00 4 Sickle Cell Disease (SCD) and Nephropathy
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI) Ended
  2024-511857-23-00 4 cancerology
• An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma Ended
  2024-511949-19-00 1 Metastatic Melanoma
• Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Ended
  2024-512754-16-01 5 Prostate cancer
• A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS … Ended
  2024-512804-20-00 5 Metastatic Colorectal Cancer
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart i … Ended
  2024-512986-15-00 4 Sjögren’s Disease
• A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How … Ended
  2024-513639-26-00 3 Multiple Sclerosis (MS)
• IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reac … Ended
  2024-513887-25-00 4 AL Amyloidosis
• An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA r … Ended
  2024-514855-13-00 4 DNA repair-deficient or platinum-sensitive solid tumors
• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer
• Double blind, multicentre, randomized, placebo-controlled trial to evaluate safety and efficacy of pitolisant in children from 6 to less tha … Ended
  2024-515568-30-00 5 Narcolepsy
• Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA Ended
  2024-516028-33-01 5 HIV infection
• Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended
  2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b
• DCC-3084 monotherapy in patients with solid tumors Ended
  2024-517829-12-00 7 Solid tumors driven by the MAPK Pathway
• LONG-TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AN … Ended
  2024-517925-25-00 4 prader-willi syndrome
• C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors Ended
  2024-517988-23-00 1 KRAS mutated advanced solid tumors

Showing 2,257–2,280 of 2,286 trials